2014
DOI: 10.1016/j.yrtph.2014.04.004
|View full text |Cite
|
Sign up to set email alerts
|

Safety assessment of the calcium-binding protein, apoaequorin, expressed by Escherichia coli

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
3
0

Year Published

2015
2015
2021
2021

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 7 publications
(3 citation statements)
references
References 22 publications
(24 reference statements)
0
3
0
Order By: Relevance
“…Results suggest the in silico assessment support that this protein is not a known allergen or likely to cross react with known allergens and exhibits a digestibility profile similar to other nonallergic dietary proteins. 12 Previous work reported in a 90-day subchronic oral gavage toxicity test, at dose levels of 92.6, 462.9, and 926.0 mg/kg/ day (corresponding to 66.7, 333.3, and 666.7 mg/kg/day of apoaequorin), demonstrated that this protein has no toxicity by oral exposure in Sprague-Dawley rodents. Administration of lyophilized apoaequorin protein powder (LAPP) at levels up to 926.0 mg/kg/day did not cause adverse effects in male and female rats with a NOAEL of apoaequorin protein established at 666.7 mg/kg/day, the highest dose tested.…”
Section: Introductionmentioning
confidence: 97%
See 1 more Smart Citation
“…Results suggest the in silico assessment support that this protein is not a known allergen or likely to cross react with known allergens and exhibits a digestibility profile similar to other nonallergic dietary proteins. 12 Previous work reported in a 90-day subchronic oral gavage toxicity test, at dose levels of 92.6, 462.9, and 926.0 mg/kg/ day (corresponding to 66.7, 333.3, and 666.7 mg/kg/day of apoaequorin), demonstrated that this protein has no toxicity by oral exposure in Sprague-Dawley rodents. Administration of lyophilized apoaequorin protein powder (LAPP) at levels up to 926.0 mg/kg/day did not cause adverse effects in male and female rats with a NOAEL of apoaequorin protein established at 666.7 mg/kg/day, the highest dose tested.…”
Section: Introductionmentioning
confidence: 97%
“…Results suggest the in silico assessment support that this protein is not a known allergen or likely to cross react with known allergens and exhibits a digestibility profile similar to other nonallergic dietary proteins. 12…”
Section: Introductionmentioning
confidence: 99%
“…In addition to this potential utilization, jellyfish are extremely rich in secondary metabolites that could find interesting applications in biotechnological fields [ 23 ]. Recently, a commercial product named Prevagen ® , a dietary supplement containing apoaequorin, a protein extracted from the jellyfish Aequorea victoria, has been demonstrated to bind calcium in the brain, improving the electrical signals between nerve cells and contributing to prevent dementia and Alzheimer’s disease [ 24 , 25 ].…”
Section: Introductionmentioning
confidence: 99%